Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
optical tags : Disease save search
Unraveling the Shifting Rare Eye Diseases Market Landscape: Analysis of Retinoblastoma Market, Retinitis Pigmentosa Market, Limbal Stem Cell Deficiency Market, Leber Hereditary Optic Neuropathy Market, and Stargardt Disease Market | DelveInsight
Published: 2023-11-16 (Crawled : 22:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -2.04%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 0.63% 0
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: -2.65%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
NVS | News | $92.79 -0.31% 210K
|
Health Technology
|
| O: 0.91%
H: 0.21%
C: -0.01%
JNJ | News | $145.08 0.21% 2M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
GSK | $39.38 -0.56% 310K
|
Health Technology
|
| O: 1.05%
H: 1.44%
C: 1.15%
ABT | News | $105.97 0.07% 920K
|
Health Technology
|
| O: 2.58%
H: 0.0%
C: 0.0%
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
rare disease cell eye market
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-11-16 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 1.08%
C: -0.54%
tepezza treatment thyroid disease active japan eye trial therapeutics
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.97%
H: 0.38%
C: -2.35%
treatment eye eye disease trial therapeutics disease active phase 3
Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications
Published: 2021-10-15 (Crawled : 12:15) - globenewswire.com
BNGO | News | $0.73 -10.52% 1.6M
|
Health Technology
|
| O: 1.31%
H: 0.18%
C: -4.62%
presentation disease genetic optical application genomic cancer research
Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies
Published: 2021-07-07 (Crawled : 15:15) - globenewswire.com
BNGO | News | $0.73 -10.52% 1.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: -4.26%
disease genetic optical genomic
Bionano Chief Medical Officer Presents Vision for Optical Genome Mapping as a First Line Clinical Tool for Cancer and Genetic Disease Testing at Festival of Genomics & Biodata
Published: 2021-01-27 (Crawled : 13:04) - globenewswire.com
BNGO | News | $0.73 -10.52% 1.6M
|
Health Technology
|
| O: -10.4%
H: 9.69%
C: 0.91%
test genomic disease cancer optical genetic
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.